Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 481 to 490 of 2450 total matches.
Two Drugs for Sickle Cell Disease: Crizanlizumab (Adakveo) and Voxelotor (Oxbryta)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
and hemolysis, and decreases the
frequency of painful crises and blood transfusions.1
Blood transfusions ...
The FDA has approved two new drugs for sickle cell
disease: crizanlizumab-tmca (Adakveo – Novartis), an
IV P-selectin blocker, and voxelotor (Oxbryta – GBT),
an oral hemoglobin S (HbS) polymerization inhibitor.
Intravenous Cetirizine (Quzyttir) for Acute Urticaria
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
than IV diphenhydramine, but costs much more.
Table 1. Pharmacology
Class Second-generation H1 ...
Quzyttir (TerSera), an IV formulation of the second-generation
H1-antihistamine cetirizine, has been
approved by the FDA for treatment of acute urticaria in
patients ≥6 months old. Oral formulations of cetirizine
(Zyrtec, and others) have been for sale over the counter
for years. Quzyttir is the first parenteral formulation
of a second-generation H1-antihistamine to become
available in the US; parenteral formulations of two
first-generation H1-antihistamines, diphenhydramine
(Benadryl, and others) and hydroxyzine (Vistaril, and
others), have been available for many...
Some Drugs for COVID-19
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
these cells via ACE2 receptors.1 Others have suggested, however, that ACE2 may protect against lung injury ...
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Table: Treatments Considered for COVID-19 (Archived) (online only)
The Medical Letter on Drugs and Therapeutics • Apr 06, 2020 (Issue 1595)
2 days, then 500 mg once/day x 12 days2,3
OR
1 g on day 1, then 500mg once daily x 4-7days ...
View the Table: Treatments Considered for COVID-19
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.1,2 IBS ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant bowel
symptom as IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed type (IBS-M), or unclassified
(IBS-U). Alterations in the microbiome, stress
responses, sensory and motor function of the gut,
and host genetic factors may be contributing factors.
Since the exact cause of IBS is unknown, the goal of
treatment is symptom control.
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • Mar 23, 2020 (Issue 1594)
or on its effects on the
breastfed infant or milk production
1. Lactmed. Available ...
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
or severe hepatic impairment (Child-Pugh
B/C) or severe renal impairment is not recommended.
Table 1 ...
Consensi (Coeptis/Burke), a fixed-dose combination
of the calcium channel blocker amlodipine (Norvasc,
and others) and the COX-2 selective NSAID celecoxib
(Celebrex, and generics), has been approved by the FDA
for treatment of patients who have hypertension and
osteoarthritis.
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
for treatment of
moderate to severe migraine.1 The pain freedom rate
at 2 hours after administration ...
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine with or
without aura in adults.
Peanut Allergen Powder (Palforzia)
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
group than in the placebo group (see Table 1).4
ADVERSE EFFECTS — The most common adverse
effects ...
The FDA has approved peanut allergen powder-dnfp
(Palforzia – Aimmune) for use as oral immunotherapy
to mitigate allergic reactions, including anaphylaxis,
caused by accidental peanut exposure in patients with
a confirmed peanut allergy. It is the first drug to be
approved in the US for this indication; Viaskin Peanut,
an immunotherapy patch, is under FDA review for the
same indication.
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
10 issue.1 On February 23, the American Society of
Retina Specialists reported that 14 patients who ...
We reviewed brolucizumab (Beovu – Novartis) for treatment
of neovascular (wet) age-related macular degeneration in our
February 10 issue. On February 23, the American Society of
Retina Specialists reported that 14 patients who received the
drug have developed retinal vasculitis, a potentially vision-threatening
complication.